Kodu・Aktsiate loetelu・Collegium Pharmaceutical Inc

C
Collegium Pharmaceutical Inc

Suletud

SektorTervishoid

35.58 0.71

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

34.65

Max

35.79

Põhinäitajad
By Trading Economics
Sissetulek	-2.5M 14M
Müük	-12M 194M
P/E Sektori keskmine	17.077 64.641
Aktsiakasum	1.76
Kasumimarginaal	7.491
Töötajad	423
EBITDA	-213M 91M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+61.13% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	31M 1.2B
Eelmine avamishind	34.87
Eelmine sulgemishind	35.58

Uudiste sentiment

By Acuity

34%

66%

104 / 340 Pingereas Healthcare

Collegium Pharmaceutical Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 19:46 UTC

Collegium Pharmaceutical Inc is trading lower today, continuing a three-session decline. The stock peaked early but has since pulled back.

31. juuli 2026, 20:06 UTC

News

Collegium Pharmaceutical is under scrutiny due to concerns over its financial performance, contributing to a decline in shares during Friday's session.

30. juuli 2026, 20:09 UTC

Collegium Pharmaceutical Inc shares are lower in Thursday's session, with no specific news to explain the decline amid broader market volatility.

29. juuli 2026, 22:01 UTC

Collegium Pharmaceutical Inc is trading higher in after-market hours, continuing a positive trend with gains over four consecutive sessions amid cautious investor sentiment.

28. juuli 2026, 22:01 UTC

Collegium Pharmaceutical Inc shares are lower in after-market hours, continuing a decline from Tuesday's close amid broader market pressures, particularly in Asia.

27. juuli 2026, 19:07 UTC

News

Collegium Pharmaceutical reported first-quarter revenues of $193.5 million, surpassing expectations, while shares are trading higher amid broader strength in the pharmaceutical sector.

24. juuli 2026, 19:46 UTC

Collegium Pharmaceutical Inc shares are lower during Friday's session, with no specific news identified to explain the decline. The stock remains near its one-month trading range.

22. juuli 2026, 20:01 UTC

Collegium Pharmaceutical Inc shares are lower today, continuing a downward trend seen since Tuesday's close, with no specific news identified for the decline.

21. juuli 2026, 20:01 UTC

Collegium Pharmaceutical Inc is trading higher amid a broader market rally, with the Pharmaceuticals sector also gaining momentum. No specific news was identified.

20. juuli 2026, 19:41 UTC

News

Collegium Pharmaceutical plans to move its headquarters to Boston in 2027. Shares are lower amid significant declines in the Pharmaceuticals sub-sector.

Võrdlus sarnastega

Hinnamuutus

Collegium Pharmaceutical Inc Prognoos

Hinnasiht

By TipRanks

61.13% tõus

12 kuu keskmine prognoos

Keskmine 57.33 USD 61.13%

Kõrge 60 USD

Madal 56 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Collegium Pharmaceutical Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Collegium Pharmaceutical Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

104 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.